Biohaven (BHVN) Projected to Release Earnings on Monday

Posted by Stanley Muller on Aug 3rd, 2026

Biohaven (NYSE:BHVN – Get Free Report) is anticipated to announce its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect Biohaven to announce earnings of ($0.7610) per share and revenue of $0.49 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Biohaven (NYSE:BHVN – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). On average, analysts expect Biohaven to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Biohaven Trading Down 0.0%

NYSE BHVN opened at $13.49 on Monday. The company has a debt-to-equity ratio of 1.87, a quick ratio of 7.41 and a current ratio of 7.41. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of -2.38 and a beta of 1.28. The company’s 50-day simple moving average is $13.60 and its two-hundred day simple moving average is $11.56. Biohaven has a one year low of $7.48 and a one year high of $18.57.

Institutional Trading of Biohaven

Several hedge funds have recently modified their holdings of the company. PNC Financial Services Group Inc. boosted its holdings in shares of Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after buying an additional 1,268 shares in the last quarter. Arax Advisory Partners grew its holdings in Biohaven by 943.3% in the fourth quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock worth $55,000 after purchasing an additional 4,443 shares during the last quarter. Focus Partners Wealth acquired a new stake in shares of Biohaven in the 3rd quarter worth $87,000. Tower Research Capital LLC TRC increased its position in Biohaven by 198.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,031 shares of the company’s stock valued at $113,000 after buying an additional 5,341 shares in the last quarter. Finally, Quantbot Technologies LP raised its stake in Biohaven by 1,097.8% in the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock valued at $125,000 after buying an additional 8,102 shares during the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BHVN shares. Canaccord Genuity Group assumed coverage on shares of Biohaven in a research report on Monday, April 13th. They issued a “buy” rating and a $21.00 price target for the company. Wall Street Zen raised shares of Biohaven from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Morgan Stanley lowered their target price on Biohaven from $21.00 to $18.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $10.00 target price on shares of Biohaven in a research report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.62.

Check Out Our Latest Analysis on Biohaven

Biohaven Company Profile

(Get Free Report)

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.